Autopsy report · NCT05572463
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Cause of deathFunding or business
“Sponsor Strategy”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1, Phase 2
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Conditions
- Unresectable Cutaneous Melanoma; Metastatic Cutaneous Melanoma
- Interventions
- Sintilimab + IBI110
- Participants
- 0
- Sites
- 13
- Countries
- Australia, France, Germany, Spain, Switzerland, United Kingdom, United States
Trials that died the same way
- Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
“sponsor strategy change” - POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
“Change in Sponsor strategy” - Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
“Strategic sponsor decision” - Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
“Sponsor's strategic decision” - Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
“Strategic decision of Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.